Product
CPI-613 (devimistat)
PHARMACEUTICAL
byCornerstone Pharmaceuticals
United States (US)
ABOUT THE PRODUCT
A lead drug candidate undergoing clinical trials for the treatment of cancer. It targets enzymes involved in cancer cell energy metabolism.
Information is owner-confirmed
Last updated 0 month ago
Price range